ALACHUA, FL -- (MARKET WIRE) -- April 03, 2007 -- Oragenics, Inc. (AMEX: ONI), a biotechnology development company, announced today that it has been awarded a grant to undertake a clinical research collaboration in the field of colorectal cancer utilizing its proprietary Change Mediated Antigen Technology (CMAT™). The grant, awarded through the Small Business Innovation Research (SBIR) program of the National Cancer Institute (NCI), will support a joint effort by scientists and clinicians at Oragenics and the Lankenau Institute of Medical Research (LIMR) to identify biomarkers of colorectal cancer in early, middle and late stages of the disease.
